ATR-12
Netherton Syndrome
Phase 1Active; First-in-human trial anticipated in 2023
Key Facts
Indication
Netherton Syndrome
Phase
Phase 1
Status
Active; First-in-human trial anticipated in 2023
Company
About Azitra
Azitra is a clinical-stage biopharmaceutical company focused on creating novel therapeutics for skin diseases through microbial and protein engineering. Its core technology platform includes a library of approximately 1,500 unique bacterial strains, augmented by AI/ML and licensed genetic engineering tools, to develop engineered strains of Staphylococcus epidermidis and therapeutic proteins. The company's pipeline targets high-need conditions like Netherton syndrome, EGFR inhibitor-associated rash, and ichthyosis vulgaris, positioning it at the forefront of the emerging live biotherapeutic product field in dermatology.
View full company profileTherapeutic Areas
Other Netherton Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| BCX17725 | BioCryst Pharmaceuticals | Pre-Clinical/Phase 1 |
| QRX003 | Quoin Pharmaceuticals | Phase 3 |